聚乙二醇化干扰素α-2a治疗HBeAg阴性的慢性乙肝药物经济学分析  

PEG-IFN α-2a for HbeAg Negative Type B Chronic Hepatitis:Pharmacoeconomic Analysis

作　　者：龙华[1] 贺爱辉[1] 梁少媚[1] 

机构地区：[1]广东药学院附属第一医院,广州市510080

出　　处：《中国医院用药评价与分析》2008年第9期683-685,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨聚乙二醇化干扰素α-2a治疗HBeAg阴性的慢性乙型肝炎的临床效果和经济效果。方法:运用成本-效果分析法对56例HBeAg阴性的慢性乙型肝炎患者分别用聚乙二醇化干扰素α-2a和干扰素两种方案治疗的结果进行比较。结果:聚乙二醇化干扰素组疗效对比干扰素组有显著差异,且?OBJECTIVE： To discuss the clinical efficacy and economic effects of PEG - IFNα - 2a in the treatment of type B chronic hepatitis. METHODS： The cost- effectiveness of PEG- IFNα- 2a versus interferon （IFN） in the treatment of type B chronic hepatitis was evaluated comparatively. RESULTS： There were significant differences in clinical efficacy between PEG- IFNα- 2a and interferon （IFN） in the treatment of type B chronic hepatitis, and the costeffectiveness ratio in the former group was lower than in the latter one. CONCLUSION： As a new antiviral drug, PEG - IFNα - 2a showed a satisfactory cost - effectiveness ratio in the treatment of type B chronic hepatitis and its development enjoys promising future.

关 键 词：聚乙二醇化干扰素 乙型肝炎 HBEAG阴性 药物经济学 成本-效果比 

分 类 号：R978.7[医药卫生—药品]